PURPOSE: To review the data regarding a new antipsychotic, cariprazine.
CONCLUSIONS: Cariprazine is a dopamine D3, D2 partial agonist, with greater 
affinity to D3. It has been examined for schizophrenia, bipolar mania, bipolar 
depression, and unipolar depression. It has demonstrated efficacy in 
schizophrenia and mania, and has recently been approved by the U.S. Food and 
Drug Administration. However, it has a more inconsistent effect in depression, 
both unipolar and bipolar. Adverse effects include extrapyramidal symptoms, 
akathisia, and gastrointestinal distress.
PRACTICE IMPLICATIONS: Cariprazine will be a promising addition in the treatment 
of patients with acute mania and schizophrenia.